Wave Life Sciences Ltd. (WVE)
Largest Insider Buys in Sector
WVE Stock Price History Chart
WVE Stock Performance
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Insider Activity of Wave Life Sciences Ltd.
Over the last 12 months, insiders at Wave Life Sciences Ltd. have bought $21.5M and sold $272,540 worth of Wave Life Sciences Ltd. stock.
On average, over the past 5 years, insiders at Wave Life Sciences Ltd. have bought $21.5M and sold $1.35M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $125M. GSK plc (10 percent owner) — $16.5M.
The last purchase of 1,000,000 shares for transaction amount of $5M was made by RA CAPITAL MANAGEMENT, L.P. () on 2023‑12‑11.
List of Insider Buy and Sell Transactions, Wave Life Sciences Ltd.
| 2024-04-03 | Sale | Moran Kyle | Chief Financial Officer | 15,630 0.0133% | $6.17 | $96,421 | -1.52% | |
| 2023-12-11 | RA CAPITAL MANAGEMENT, L.P. | 1M 1.2134% | $5.00 | $5M | +26.02% | |||
| 2023-12-07 | GSK plc | 10 percent owner | 3.3M 3.4922% | $5.00 | $16.5M | +9.53% | ||
| 2023-08-23 | Sale | Moran Kyle | Chief Financial Officer | 37,062 0.0365% | $4.75 | $176,119 | +8.67% | |
| 2023-02-16 | Sale | BOLNO PAUL | President and CEO | 29,400 0.0251% | $4.04 | $118,776 | -5.01% | |
| 2023-02-16 | Sale | Vargeese Chandra | See Remarks | 10,249 0.0087% | $4.03 | $41,303 | -5.01% | |
| 2023-02-16 | Sale | Moran Kyle | Chief Financial Officer | 9,729 0.0083% | $4.04 | $39,305 | -5.01% | |
| 2023-02-16 | Sale | Francis Chris | See Remarks | 10,258 0.0087% | $4.03 | $41,340 | -5.01% | |
| 2022-05-04 | Sale | BOLNO PAUL | President and CEO | 33,501 0.0447% | $1.72 | $57,622 | +106.19% | |
| 2022-05-04 | Sale | Vargeese Chandra | See Remarks | 16,714 0.0223% | $1.72 | $28,748 | +106.19% | |
| 2022-05-04 | Sale | Panzara Michael A. | See Remarks | 16,714 0.0223% | $1.72 | $28,748 | +106.19% | |
| 2022-05-04 | Sale | Francis Chris | See Remarks | 10,867 0.0145% | $1.72 | $18,691 | +106.19% | |
| 2022-05-04 | Sale | Moran Kyle | Chief Financial Officer | 5,021 0.0067% | $1.72 | $8,636 | +106.19% | |
| 2022-02-16 | Sale | BOLNO PAUL | President and CEO | 33,150 0.0438% | $2.32 | $76,908 | +18.28% | |
| 2022-02-16 | Sale | Vargeese Chandra | Chief Technology Officer | 10,603 0.014% | $2.32 | $24,599 | +18.28% | |
| 2022-02-16 | Sale | Panzara Michael A. | See Remarks | 10,603 0.014% | $2.31 | $24,493 | +18.28% | |
| 2022-02-16 | Sale | Moran Kyle | Chief Financial Officer | 9,204 0.0121% | $2.31 | $21,261 | +18.28% | |
| 2022-02-16 | Sale | Francis Chris | See Remarks | 10,123 0.0133% | $2.31 | $23,384 | +18.28% | |
| 2021-02-16 | Sale | BOLNO PAUL | President and CEO | 11,205 0.0228% | $10.57 | $118,437 | -44.23% | |
| 2021-02-16 | Sale | Panzara Michael A. | See Remarks | 2,929 0.006% | $10.57 | $30,960 | -44.23% |
Insider Historical Profitability
| RA CAPITAL MANAGEMENT, L.P. | 18202009 15.2943% | $4.38 | 6 | 0 | +47.04% | |
| GSK plc | 10 percent owner | 13983761 11.7499% | $4.38 | 1 | 0 | |
| Moran Kyle | Chief Financial Officer | 33921 0.0388% | $4.38 | 0 | 6 | |
| Tanaka Masaharu | 2774118 2.331% | $4.38 | 2 | 3 | +2.01% | |
| TAKANASHI KEN | 1984130 1.6672% | $4.38 | 2 | 0 | +2.01% | |
| BOLNO PAUL | President and CEO | 407425 0.3423% | $4.38 | 0 | 15 | |
| Panzara Michael A. | See Remarks | 109103 0.0917% | $4.38 | 0 | 10 | |
| Vargeese Chandra | See Remarks | 106624 0.0896% | $4.38 | 0 | 11 | |
| Francis Chris | See Remarks | 79714 0.067% | $4.38 | 0 | 13 | |
| Verdine Gregory L. | director | 30000 0.0252% | $4.38 | 0 | 3 | |
| Regnante Keith | Chief Financial Officer | 15686 0.0132% | $4.38 | 0 | 3 | |
| Gaiero David G | Interim CFO | 6392 0.0054% | $4.38 | 0 | 1 |
Institutional Investor Ownership
| RA Capital Management, L.P. | $112.31M | 14.86 | 18.2M | 0% | +$0 | 0.11 | |
| Maverick Capital Ltd | $47.44M | 6.28 | 7.69M | -8.99% | -$4.69M | 0.93 | |
| M28 Capital Management Lp | $43.19M | 5.72 | 7M | -5.06% | -$2.3M | 35.52 | |
| BlackRock | $39.34M | 5.21 | 6.38M | +18.8% | +$6.23M | <0.01 | |
| 683 Capital Management Llc | $33.01M | 4.37 | 5.35M | -4.46% | -$1.54M | 3.71 | |
| Adage Capital Partners Gp L L C | $32.09M | 4.25 | 5.2M | -13.13% | -$4.85M | 0.06 | |
| Bellevue Group | $25.26M | 3.34 | 4.09M | -8.9% | -$2.47M | 0.39 | |
| Artal Group S A | $25M | 3.31 | 4.05M | +34.71% | +$6.44M | 0.13 | |
| Kynam Capital Management Lp | $24.26M | 3.21 | 3.93M | 0% | +$0 | 0.31 | |
| PRIMECAP Management Co | $17.75M | 2.35 | 2.88M | -23.49% | -$5.45M | 0.01 | |
| Point72 Asset Management | $12.18M | 1.61 | 1.97M | -38.55% | -$7.64M | 0.02 | |
| Geode Capital Management | $11.8M | 1.56 | 1.91M | +31.03% | +$2.8M | <0.01 | |
| T. Rowe Price | $11.48M | 1.52 | 1.86M | +14.37% | +$1.44M | <0.01 | |
| The Vanguard Group | $11.32M | 1.5 | 1.83M | +39.75% | +$3.22M | <0.0001 | |
| Millennium Management LLC | $10.09M | 1.34 | 1.64M | +217.85% | +$6.92M | 0.01 | |
| State Street | $9.34M | 1.24 | 1.51M | +19.84% | +$1.55M | <0.0001 | |
| Fidelity Investments | $7.21M | 0.95 | 1.17M | -2.78% | -$206,337.13 | <0.0001 | |
| Woodline Partners LP | $5.85M | 0.77 | 948,444 | -31.84% | -$2.73M | 0.06 | |
| Morgan Stanley | $5.83M | 0.77 | 945,120 | +396.57% | +$4.66M | <0.0001 | |
| Laurion Capital Management LP | $5.38M | 0.71 | 871,500 | -18.66% | -$1.23M | 0.15 | |
| Northern Trust | $4.67M | 0.62 | 757,291 | +20.89% | +$807,288.89 | <0.01 | |
| PLATINUM INVESTMENT MANAGEMENT LTD | $3.7M | 0.49 | 600,155 | -8.42% | -$340,435.89 | 0.05 | |
| Ikarian Capital LLC | $3.64M | 0.48 | 590,088 | New | +$3.64M | 1.04 | |
| Driehaus Capital Management LLC | $3.45M | 0.46 | 559,796 | -4.73% | -$171,396.41 | 0.04 | |
| Newtyn Management | $3.08M | 0.41 | 500,000 | -1.96% | -$61,700.00 | 0.67 | |
| Silverarc Capital Management Llc | $3.06M | 0.41 | 495,471 | New | +$3.06M | 0.9 | |
| Connor Clark & Lunn Investment Management Ltd | $2.85M | 0.38 | 462,582 | New | +$2.85M | 0.01 | |
| JPMorgan Chase | $2.81M | 0.37 | 455,811 | -1.49% | -$42,610.02 | <0.0001 | |
| Charles Schwab | $2.68M | 0.35 | 433,577 | +155.51% | +$1.63M | <0.01 | |
| Two Sigma | $2.57M | 0.34 | 416,725 | +1,470% | +$2.41M | <0.01 | |
| Wellington Management Company | $2.46M | 0.33 | 399,099 | +45.61% | +$771,287.07 | <0.0001 | |
| Goldman Sachs | $2.1M | 0.28 | 340,678 | -12.9% | -$311,301.14 | <0.0001 | |
| AllianceBernstein | $2.08M | 0.28 | 336,589 | +2,728.48% | +$2M | <0.01 | |
| Marshall Wace | $1.93M | 0.26 | 313,405 | -37.34% | -$1.15M | <0.01 | |
| Affinity Asset Advisors | $1.77M | 0.23 | 286,585 | New | +$1.77M | 0.31 | |
| D. E. Shaw & Co. | $1.76M | 0.23 | 285,092 | New | +$1.76M | <0.01 | |
| Td Asset Management Inc | $1.55M | 0.21 | 251,946 | +22.45% | +$285,054.03 | <0.01 | |
| Jacobs Levy Equity Management | $1.49M | 0.2 | 241,860 | +13.88% | +$181,910.09 | 0.01 | |
| Nuveen | $1.38M | 0.18 | 223,350 | +7.5% | +$96,122.40 | <0.0001 | |
| BNY Mellon | $1.22M | 0.16 | 197,878 | +9.68% | +$107,728.09 | <0.0001 | |
| Boothbay Fund Management LLC | $1.06M | 0.14 | 171,926 | New | +$1.06M | 0.04 | |
| Renaissance Technologies | $1.02M | 0.13 | 164,620 | +1,019.86% | +$925,274.69 | <0.01 | |
| Swiss National Bank | $965,605.00 | 0.13 | 156,500 | +2.69% | +$25,297.00 | <0.01 | |
| Prelude Capital | $890,331.00 | 0.12 | 144,300 | New | +$890,331.00 | 0.06 | |
| The Manufacturers Life Insurance Company | $832,185.00 | 0.11 | 134,876 | +1.1% | +$9,069.90 | <0.01 | |
| Credit Suisse | $794,203.00 | 0.11 | 128,720 | +15% | +$103,588.21 | <0.01 | |
| RhumbLine Advisers | $751,136.00 | 0.1 | 121,742 | +6.24% | +$44,096.28 | <0.01 | |
| Arrowstreet Capital, Limited Partnership | $702,000.00 | 0.09 | 113,840 | New | +$702,000.00 | <0.01 | |
| Trexquant Investment LP | $694,939.00 | 0.09 | 112,632 | +250.67% | +$496,764.90 | 0.01 | |
| Franklin Templeton Investments | $599,366.00 | 0.08 | 97,142 | New | +$599,366.00 | <0.0001 |